Reviewer's report

Title: Safety and efficacy of vemurafenib in end stage renal failure.

Version: 1 Date: 9 October 2013

Reviewer: Adil Daud

Reviewer's report:

This interesting case report describes a patient who was treated with 960 mg po BID of vemurafenib on renal dialysis. the patient had a V600K mutation and was treated while on CAPD. he developed QTc prolongation and was dose reduced and then tolerated treatment for several months and had a sustained reduction in his tumor.

The case report is clear and well written; it does need some editorial intervention and typos etc need to be fixed but is otherwise a good addition to the literature

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

research funding from Genentech, GSK, Merck, Pfizer. Consultant for OncoSec and GSK